生育治疗中的卵巢刺激与乳腺癌风险:一项匹配队列研究
这项回顾性、人群基础的队列研究纳入1994至2019年间接受ART或MAR治疗及未接受生育治疗的女性的数据。ART组乳腺癌粗风险与一般人群相似(HR=1.10,95%CI 0.94-1.28),与MAR组也相似(HR=1.00,95%CI 0.86-1.16)。作者认为接受生育治疗的女性和临床医生可对辅助生殖技术在绝经前乳腺癌风险方面的安全性感到安心。
要点
- ART组与一般人群的乳腺癌粗风险相似(HR=1.10,95%CI 0.94-1.28)。
- ART组与MAR组的乳腺癌粗风险相似(HR=1.00,95%CI 0.86-1.16)。
- ART组中乳腺癌与ART周期数或重组/尿源性药物使用无相关性。
核心结论
- ART治疗后的乳腺癌发生率与一般人群或MAR治疗后相当。
- 接受生育治疗的女性和临床医生可对辅助生殖技术在绝经前乳腺癌风险方面的安全性感到安心。
研究设计与样本
- 回顾性、人群基础的队列研究,纳入1994至2019年间接受ART或MAR治疗及未接受生育治疗的女性的数据。
- ART组女性按出生年份和首次分娩年份或无产次状态与MAR组女性和一般育龄女性各1:1匹配,MAR组女性还按治疗开始日历年与ART组女性匹配。
- 所有纳入女性均为Maccabi Healthcare Services成员,数据来自电子健康记录计算机数据库。
主要发现
- 共984名女性(1.0%)被诊断为乳腺癌,平均随访期为9.1±6.3年,四分位距(IQR)为3.8-13.7年。
- ART组、MAR组和一般人群的乳腺癌发病率分别为每10000人年11.9(95%CI 10.7-13.3)、10.7(95%CI 9.6-11.9)和10.7(95%CI 9.6-12.0)。
- ART组与一般人群的乳腺癌粗风险相似(HR=1.10,95%CI 0.94-1.28),ART组与MAR组的粗风险也相似(HR=1.00,95%CI 0.86-1.16)。
- 进一步调整年龄、BMI、吸烟、社会经济状况和产次后,乳腺癌风险比无实质性影响(ART vs 一般人群:HR=1.10,95%CI 0.94-1.28;ART vs MAR:HR=0.99,95%CI 0.85-1.16)。
关键数值与推荐
- 在诊断为乳腺癌的女性中,ART组、MAR组和一般人群组的BRCA1/2突变患病率和肿瘤分期无差异。
- 在ART组女性中,乳腺癌与ART周期数或重组药物或尿源性药物的使用无相关性。
临床怎么用
- 接受生育治疗的女性和临床医生可对辅助生殖技术在绝经前乳腺癌风险方面的安全性感到安心。
局限性
- 随访结束时女性平均年龄仅为42岁,因此研究不足以检测绝经后乳腺癌风险的潜在差异。
- 未按不孕原因对暴露患者进行亚分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is there a difference in the breast cancer risk among women who underwent ART treatments compared to those who underwent medically assisted reproduction (MAR) infertility treatments or women of reproductive age in the general population? SUMMARY ANSWER: The risk of breast cancer among women treated by ART was similar to the risk among women treated by MAR and women who did not undergo fertility treatments. WHAT IS KNOWN ALREADY: Studies investigating breast cancer risk in women who have undergone fertility treatments have provided conflicting results. STUDY DESIGN, SIZE, DURATION: A retrospective, population-based cohort study included women who underwent ART or MAR treatments and women who did not undergo fertility treatments from 1994 to 2019. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women who underwent ART were matched one to one with women who underwent MAR treatments and one to one with woman from the general population of reproductive age, by year of birth and year of first delivery or nulliparity status. MAR women were also matched to ART women by treatment initiation calendar year. All included women were members of Maccabi Healthcare Services. Data regarding demographics, fertility treatments, BRCA mutation and possible confounders were obtained from the computerized database of electronic health records. The incidence of breast cancer after fertility treatments was compared to the matched controls. MAIN RESULTS AND THE ROLE OF CHANCE: Of 8 25 721 women of reproductive age, 32 366 women who underwent ART were matched with patients treated by MAR (n = 32 366) and 32 366 women of reproductive age. A total of 984 women (1.0%) were diagnosed with breast cancer (mean follow-up period, 9.1 ± 6.3 years; interquartile range [IQR], 3.8-13.7 years). The incidence rates of breast cancer per 10 000 person-years were 11.9 (95% CI, 10.7-13.3), 10.7 (95% CI, 9.6-11.9) and 10.7 (95% CI, 9.6-12.0) in the ART group, MAR group and general population, respectively. The crude risk for breast cancer was similar in the ART group compared with the general population (hazard ratio (HR) = 1.10, 95% CI, 0.94-1.28) and in the ART group compared with the MAR group (HR = 1.00, 95% CI, 0.86-1.16). Further adjustment for age, BMI, smoking, socioeconomic status and parity did not substantially impact the hazard rates for breast cancer (ART vs general population: HR = 1.10, 95% CI, 0.94-1.28; ART vs MAR: HR = 0.99, 95% CI, 0.85-1.16). Among women diagnosed with breast cancer, the prevalence of BRCA1/2 mutations and tumour staging did not differ between the ART, MAR and general population groups. Among women who underwent ART, no correlation was found between breast cancer and the number of ART cycles or the use of recombinant medications or urine-derived medications. LIMITATIONS, REASONS FOR CAUTION: The mean age of women at the end of follow-up was only 42 years thus the study was not powered to detect potential differences in the risk of postmenopausal breast cancer. In addition, we did not sub-classify the exposed patients by the reason for infertility. WIDER IMPLICATIONS OF THE FINDINGS: Breast cancer incidence following ART was comparable to that in the general population or following MAR. Women undergoing fertility treatments and their clinicians may be reassured about the safety of assisted reproduction technologies in terms of premenopausal breast cancer risk. STUDY FUNDING/COMPETING INTEREST(S): No specific funding was used and there are no competing interests. TRIAL REGISTRATION NUMBER: N/A.
引用
- Machtinger R, Fallach N, Goldstein I, et al. Ovarian stimulation for fertility treatments and risk of breast cancer: a matched cohort study. Hum Reprod. 2022. PMID: 34871410. doi:10.1093/humrep/deab270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。